Evidence map›Paper›PMID 42668485›Full record

ArticlePhysics and imaging in radiation oncology2026

Clinical indicators for dose re-optimization in magnetic resonance-guided online adaptive radiotherapy for prostate cancer.

Masato Nishitani, Hiroyuki Okamoto, Weishan Chang, Junichi Kuwahara, Takahito Chiba, Tatsuya Sakasai, Hiroki Nakayama, Koji Inaba, Tairo Kashihara, Satoshi Nakamura and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masato NishitaniDepartment of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-ogu 7-2-10, Arakawa-ku, Tokyo 116-8551, Japan.
Hiroyuki OkamotoDepartment of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-ogu 7-2-10, Arakawa-ku, Tokyo 116-8551, Japan.
Weishan ChangDepartment of Radiological Sciences, Graduate School of Human Health Sciences, Tokyo Metropolitan University, Higashi-ogu 7-2-10, Arakawa-ku, Tokyo 116-8551, Japan.
Junichi KuwaharaDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Takahito ChibaSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Tatsuya SakasaiDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Hiroki NakayamaSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Koji InabaDepartment of Radiation Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Tairo KashiharaDepartment of Radiation Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Satoshi NakamuraSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Tetsu NakaichiSection of Radiation Safety and Quality Assurance, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Tomonori GokaDepartment of Radiological Technology (Radiological Oncology), National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: This study aimed to identify dose-volume parameters and anatomical features associated with the implementation of online dose re-optimization in magnetic resonance-guided adaptive radiotherapy (ART) for prostate cancer and to evaluate its impact on target coverage and organs-at-risk dose-volume parameters. Materials and Methods: Treatment plans from 150 fractions (with and without dose re-optimization) in 30 patients receiving five-fraction stereotactic body radiotherapy were retrospectively analyzed. Evaluated parameters included planning target volume (PTV) Results: Online dose re-optimization was performed in 60% of fractions and became more frequent in later fractions ( Conclusions: Progressive target-volume expansion appears to be the primary anatomical factor associated with deterioration in target coverage. A reduction in PTV

Indexed as

Clinical indicators for dose re-optimizationMR-guided online adaptive radiotherapyTreatment planning analysis

Identifiers

PMID42668485
PMCPMC13524625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.